Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks to Buy in a Market Crash

By Brian Feroldi - Jul 8, 2015 at 10:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

My shopping list if a market crash comes to pass.

The last five years have been an absolute dream particularly for biotech investors; shares of the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) have scorched the returns of the market over that time period, up more than 400% when the market itself returned a still-impressive 133%.

SPY Chart

While this outperformance is by no means unwarranted, given the strong financial performance of many of the large biotech stocks in the ETF, biotech investors would be right to wonder if biotech stocks' valuations may be slightly ahead of themselves.

Biotech stocks tend to be more volatile than the market in general, which can lead to wild price swings when the latter turns south. Long-term biotech investors shouldn't fear such crazy price movements; rather, we should look at them as opportunities to pick up shares in our favorite biotech stocks when the market is offering a discount.

Here are three stocks on my biotech shopping list that you can bet I will be buying if the market suddenly takes a turn for the worse.

First up on my list is the largest and most profitable biotech company in the world, Gilead Sciences (NASDAQ: GILD). Gilead offers biotech investors something quite rare in the sector, which is a stunningly profitable company with strong growth prospects selling at a below-market price-to-earnings ratio. Gilead's growth has been nothing short of stellar over the past several years thanks to the incredible success of its relatively newly launched Hepatitis C drugs Sovaldi and Harvoni. These drugs should continue to grow nicely in the years ahead. The most recent approval for sale of these drugs came from Japan, where there is a tremendous market opportunity for the Gilead to treat Hepatitis C patients.  

Source: Gilead.

Gilead also recently initiated a small dividend that currently yields 1.4% and has authorized a massive $15 billion share repurchase program that should continue to meaningfully bring down the share count. And yet, all of this good news is bundled in a company that trades for around 10 times 2016 earnings estimates. Any weakness in the share price would represent a great time for investors to consider opening up a position.  

Up next on my list is Celgene Corporation (NASDAQ: CELG), which is another biotech juggernaut that has been a massive winner in recent years. The company boasts a strong portfolio of products designed to treat a variety of disease states, but the bulk of its billions in revenue come from Revlimid, which treats multiple myeloma. Revlimid sales grew an impressive 16% in 2014, and contributed almost $5 billion in sales to the company's top line. When combined with other fast-growing drugs like Abraxane, which treats breast cancer, and Pomalyst/Imnovid, which, like Revlimid, also treats multiple myeloma, sales managed to grow by more than 18% last year.

Better yet, Celgene has been using its financial strength to buy back a significant amount of stock, which has reduced the share count significantly over the past few years. When combined with strong sales growth and cost control measures, margins have expanded company-wide, which has helped turbo-charge earnings-per-share growth.

CELG Average Diluted Shares Outstanding (Annual) Chart

Investors have been very excited about Celgene's recent performance, and the stock currently trades for around 40 times trailing earnings. While this isn't exactly what I'd call a cheap stock, the company does appear to have a very bright future ahead. The management team has given guidance for 2020 of sales over $20 billion and earnings per share over $12.50, which would represent huge growth when compared to last year's $7.5 billion in sales and diluted earnings per share of $2.39. If it achieves these results, the is stock is poised to do very well in the years ahead, and it could be a great buy if the market offers us a better price. 

Last on my shopping list is a company that has a bit more spice than Gilead or Celgene as it is not yet profitable, but it could hold more upside potential: Isis Pharmaceuticals (NASDAQ: ISIS). The company is developing a cutting-edge RNA-targeting technology that is used to inhibit the production of disease-causing proteins, and it boasts a pipeline full of potential. Isis curently has 38 drugs in its pipeline aimed at treating a wide variety of disease states, and eight of those drugs are currently in phase 3 clinical trials.

Isis has a who's who list of big pharma partners it has tapped to help finance the development and potential commercialization of these drugs. These partnerships have so far provided Isis with more than $1.4 billion in cash payments, and the company has the potential to earn an additional $8.5 billion in future milestone payments if it can successfully commercialize its pipeline.

Investors have certainly taken notice of Isis' progress and have bid up the stock accordingly, with the shares up more than 300% in the last three years alone.

ISIS Chart

While I'm more than happy to pay up for a company that is performing well, ISIS could make for a great investment if the market were to punish the stock for no good reason.

Any of these companies could make a fine investment choice, even at today's more elevated prices, as each holds great growth potential in the years ahead. Still, if Mr. Market were kind enough to offer us a substantial discount on any of them, you can bet I'll be more than happy to buy in at reduced prices.

Brian Feroldi owns shares of Gilead Sciences. The Motley Fool recommends Celgene, Gilead Sciences, and Isis Pharmaceuticals. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
$45.70 (5.57%) $2.41
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.09 (-1.32%) $0.82
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
$131.44 (0.97%) $1.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.